Virax Biolabs Group Ltd [VRAX] stock is trading at $1.11, up 26.64%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The VRAX shares have gain 13.79% over the last week, with a monthly amount drifted -13.95%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Virax Biolabs Group Ltd [NASDAQ: VRAX] stock has seen the most recent analyst activity on March 31, 2025, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $3.
Virax Biolabs Group Ltd [VRAX] stock has fluctuated between $0.60 and $9.00 over the past year. Virax Biolabs Group Ltd [NASDAQ: VRAX] shares were valued at $1.11 at the most recent close of the market.
Analyzing the VRAX fundamentals
Virax Biolabs Group Ltd [NASDAQ:VRAX] reported sales of 0.08M for the trailing twelve months, which represents a drop of -93.53%. Gross Profit Margin for this corporation currently stands at 0.4% with Operating Profit Margin at -78.58%, Pretax Profit Margin comes in at -79.16%, and Net Profit Margin reading is -77.53%. To continue investigating profitability, this company’s Return on Assets is posted at -0.7, Equity is -0.94 and Total Capital is -0.76. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.9177 points at the first support level, and at 0.7255 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.3211, and for the 2nd resistance point, it is at 1.5323.
Ratios To Look Out For
For context, Virax Biolabs Group Ltd’s Current Ratio is 11.58. As well, the Quick Ratio is 11.40, while the Cash Ratio is 10.5. Considering the valuation of this stock, the price to sales ratio is 60.22, the price to book ratio is 0.33.
